CHARLESTON, WV (LOOTPRESS) – Vandalia Health Charleston Area Medical Center, in partnership with the CAMC Clinical Trials Center, has become the first site in the world to be activated for the Bioflow-48 stent study.
The hospital has also enrolled the first three patients globally.
The international study will evaluate the Orsiro® Mission 48-mm Sirolimus-Eluting Coronary Stent System, a new, longer stent designed to treat complex blockages in heart arteries.
A total of 100 participants will be enrolled across up to 35 sites, including as many as 15 in the United States.
CAMC interventional cardiologists performed the first three cases in the world. “That means that we are very advanced center,” said Dr. Haytham Alkhaimy, CAMC Interventional Cardiologist.
“We are proud to provide all the new treatments, technology and devices to our community.”
Researchers aim to determine whether the longer stent can improve patient outcomes by covering long lesions with a single device instead of multiple overlapping stents.
The CAMC Clinical Trials Center study team includes Kaylea Hoffman, Morgan Bush, Brittany Barnes, Wisam Alzoebie, and Jordan Campanelli. Investigators contributing to the study are principal investigator Elie Gharib, MD; Mitchell Rashid, MD; Elise Anderson, DO; Haytham Alkhaimy, MD; Sangeeta Mandapaka, MD; Joseph Choo, MD; and Richard Han, MD.
More information about the CAMC Clinical Trials Center is available at camcmedicine.edu/ClinicalTrials.
